Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the three months ended September 30, 2026.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the three months ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1, relevant for assessing Erasca’s cash runway and development funding needs
Item EX-99.1 · Exhibit EX-99.1
- ERAS-0015 received FDA Fast Track for metastatic pancreatic cancer, enabling closer FDA interaction but not increasing approval probability
- Three potentially registration-enabling trials remain targeted: pancreatic cancer and NSCLC programs beginning 2027
- Cash, equivalents and marketable securities reached $947.8 million, up from $341.8 million at December 31, 2025
- Quarterly R&D expense rose to $47.2 million from $22.5 million, reflecting accelerated clinical and preclinical development
- Quarterly net loss widened to $51.3 million, or $(0.15) per share, from $30.6 million, or $(0.11) per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.